KR101395515B1 - 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체 - Google Patents

항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체 Download PDF

Info

Publication number
KR101395515B1
KR101395515B1 KR1020087021791A KR20087021791A KR101395515B1 KR 101395515 B1 KR101395515 B1 KR 101395515B1 KR 1020087021791 A KR1020087021791 A KR 1020087021791A KR 20087021791 A KR20087021791 A KR 20087021791A KR 101395515 B1 KR101395515 B1 KR 101395515B1
Authority
KR
South Korea
Prior art keywords
seq
delete delete
csf
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087021791A
Other languages
English (en)
Korean (ko)
Other versions
KR20080099314A (ko
Inventor
필립 엠. 사쓰
니콜라스 이. 니콜라이데스
루이지 그라쏘
지안 리
퀴민 차오
에릭 로우티에르
볼프강 에벨
Original Assignee
모르포테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101395515(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 모르포테크, 인크. filed Critical 모르포테크, 인크.
Publication of KR20080099314A publication Critical patent/KR20080099314A/ko
Application granted granted Critical
Publication of KR101395515B1 publication Critical patent/KR101395515B1/ko
Assigned to 에이자이 아이엔씨. reassignment 에이자이 아이엔씨. 권리의 전부이전등록 Assignors: 모르포테크, 인크.
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
KR1020087021791A 2006-02-08 2007-02-08 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체 Expired - Fee Related KR101395515B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77125106P 2006-02-08 2006-02-08
US60/771,251 2006-02-08
US77450006P 2006-02-17 2006-02-17
US60/774,500 2006-02-17
PCT/US2007/061874 WO2007092939A2 (en) 2006-02-08 2007-02-08 Antigenic gm-csf peptides and antibodies to gm-csf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137029090A Division KR101486183B1 (ko) 2006-02-08 2007-02-08 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체

Publications (2)

Publication Number Publication Date
KR20080099314A KR20080099314A (ko) 2008-11-12
KR101395515B1 true KR101395515B1 (ko) 2014-05-14

Family

ID=38345964

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087021791A Expired - Fee Related KR101395515B1 (ko) 2006-02-08 2007-02-08 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
KR1020137029090A Expired - Fee Related KR101486183B1 (ko) 2006-02-08 2007-02-08 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137029090A Expired - Fee Related KR101486183B1 (ko) 2006-02-08 2007-02-08 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체

Country Status (18)

Country Link
US (5) US7741450B2 (https=)
EP (2) EP3181585A3 (https=)
JP (1) JP5210889B2 (https=)
KR (2) KR101395515B1 (https=)
CN (1) CN101501070B (https=)
AU (1) AU2007213716C1 (https=)
CA (2) CA2641169C (https=)
CY (1) CY1118709T1 (https=)
DK (1) DK1981909T3 (https=)
ES (1) ES2609088T3 (https=)
HR (1) HRP20170024T1 (https=)
HU (1) HUE032584T2 (https=)
IL (2) IL193011A (https=)
LT (1) LT1981909T (https=)
PL (1) PL1981909T3 (https=)
PT (1) PT1981909T (https=)
RS (1) RS55526B1 (https=)
WO (1) WO2007092939A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468774A3 (en) 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2641169C (en) 2006-02-08 2017-05-02 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
EP2013620A2 (en) * 2006-04-17 2009-01-14 Morphotek, Inc. Whole genome evolution technology applied to improve protein and antibody yields by cells
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
US20080206241A1 (en) * 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
US20100255513A1 (en) * 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
WO2009032845A2 (en) 2007-09-04 2009-03-12 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2217626A4 (en) * 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd EPITOP FOR NEUTRALIZING ANTIBODIES
PE20091420A1 (es) * 2007-11-13 2009-10-17 Evec Inc ANTICUERPOS MONOCLONALES ANTI hGM-CSF
JP2012105657A (ja) * 2008-02-14 2012-06-07 Evec Inc ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
JP5476310B2 (ja) * 2008-02-14 2014-04-23 株式会社イーベック ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
US8075885B2 (en) 2008-04-07 2011-12-13 Kalobios Pharmaceuticals, Inc. Methods of treating heart failure using an anti-GM-CSF antibody
NZ588850A (en) * 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
KR101681331B1 (ko) * 2008-04-29 2016-12-01 암젠 리서치 (뮌헨) 게엠베하 치료를 위한 ｇｍ-ｃｓｆ 및 ｉｌ-17의 억제제
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
EP3056217B1 (en) * 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
WO2011100637A1 (en) 2010-02-11 2011-08-18 The Board Of Trustees Of The Leland Stanford Junior University Markers for determination of patient responsiveness
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP2729498A1 (en) * 2011-07-06 2014-05-14 MorphoSys AG Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof
WO2013026059A1 (en) 2011-08-18 2013-02-21 New York University Inhibition of oncogenic kras-induced gm-csf production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CN104212760B (zh) * 2013-05-29 2017-08-08 中国科学院上海生命科学研究院 肌肉干细胞体外培养方法及其应用
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
EP3139960B1 (en) 2014-05-07 2024-01-17 Takeda Pharmaceutical Company Limited Liquid formulation comprising gm-csf neutralizing compound
ES2626491B1 (es) * 2015-12-03 2018-06-25 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpos monoclonales frente a bambi y uso para tratamiento de enfermedades inflamatorias
MX2019003019A (es) 2016-09-19 2019-09-19 I Mab Anticuerpos anti-gm-csf y usos de los mismos.
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
US11267859B2 (en) 2017-06-09 2022-03-08 The Regents Of The University Of Colorado, A Body Corporate GM-CSF mimetics and methods of making and using same
EP3691663A4 (en) 2017-10-02 2021-08-18 Humanigen, Inc. METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
CN112805301B (zh) * 2018-10-15 2023-07-21 安立玺荣生医(香港)有限公司 粒细胞-巨噬细胞集落刺激因子的抗体及其用途
SG11202103589XA (en) * 2018-10-31 2021-05-28 Humanigen Inc Materials and methods for treating cancer
WO2021207667A1 (en) * 2020-04-10 2021-10-14 Kinevant Sciences Gmbh Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
CN117384856B (zh) * 2023-09-04 2024-04-16 广州医科大学 一种永生化copd人支气管上皮细胞株及其构建方法和应用
CN120399067B (zh) * 2025-07-02 2025-09-30 武汉伊莱瑞特生物科技股份有限公司 一种与人gm-csf特异性结合的单克隆抗体及其检测试剂盒和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046330A2 (en) * 2002-11-15 2004-06-03 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5908763A (en) 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
US6013619A (en) 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
AU630496B2 (en) 1989-07-14 1992-10-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
BR9205151A (pt) 1992-08-17 1994-03-01 Praxair Technology Inc Dissolucao aumentada de gas
WO1997035882A1 (en) 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
AU2066897A (en) 1996-03-27 1997-10-17 Ortho Pharmaceutical Corporation Manufacture of liposomes and lipid-protein complexes by ethanolic injection and thin film evaporation
US6013764A (en) 1996-07-17 2000-01-11 Ortho Pharmaceutical Corp. Liquid phase peptide synthesis of KL-4 pulmonary surfactant
EP0959136A1 (en) * 1998-05-20 1999-11-24 Introgene B.V. Targeted delivery through a cationic amino acid transporter
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
CN1487996B (zh) * 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
MXPA03008032A (es) 2001-03-08 2003-12-04 Merck Patent Gmbh Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida.
US7381801B2 (en) * 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
JP2005040126A (ja) * 2003-02-28 2005-02-17 Mitsubishi Pharma Corp モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
CA2515389A1 (en) * 2003-02-28 2004-09-10 Mitsubishi Pharma Corporation Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical compostion, and diagnostic reagent
JP2007525971A (ja) 2003-08-05 2007-09-13 モルフォテック、インク． 癌に関連する変異体細胞表面分子
JP2005176792A (ja) 2003-12-24 2005-07-07 Atex Co Ltd 乗用草刈機
EP1593690B1 (en) * 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
EP2468774A3 (en) * 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
EP3620171B1 (en) 2005-05-18 2022-04-20 MorphoSys AG Anti-gm-csf antibodies and uses therefor
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2641169C (en) 2006-02-08 2017-05-02 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046330A2 (en) * 2002-11-15 2004-06-03 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization

Also Published As

Publication number Publication date
IL193011A0 (en) 2009-02-11
DK1981909T3 (en) 2017-01-23
CA2641169C (en) 2017-05-02
US20130058945A1 (en) 2013-03-07
EP1981909B1 (en) 2016-10-12
WO2007092939A2 (en) 2007-08-16
US8318168B2 (en) 2012-11-27
US20100272730A1 (en) 2010-10-28
CN101501070B (zh) 2013-12-25
US20140086928A1 (en) 2014-03-27
EP1981909A2 (en) 2008-10-22
EP3181585A2 (en) 2017-06-21
HUE032584T2 (en) 2017-09-28
WO2007092939A8 (en) 2009-07-23
KR101486183B1 (ko) 2015-01-28
CA2961031A1 (en) 2007-08-16
US8623364B2 (en) 2014-01-07
US20160333089A1 (en) 2016-11-17
AU2007213716C1 (en) 2015-05-07
EP3181585A3 (en) 2017-08-30
CA2641169A1 (en) 2007-08-16
US20080292641A1 (en) 2008-11-27
RS55526B1 (sr) 2017-05-31
WO2007092939A3 (en) 2008-03-27
JP2009526082A (ja) 2009-07-16
US9422367B2 (en) 2016-08-23
HRP20170024T1 (hr) 2017-03-10
KR20130124420A (ko) 2013-11-13
CN101501070A (zh) 2009-08-05
AU2007213716B2 (en) 2012-12-06
ES2609088T3 (es) 2017-04-18
IL235050A (en) 2017-03-30
US10023632B2 (en) 2018-07-17
AU2007213716A1 (en) 2007-08-16
PL1981909T3 (pl) 2017-08-31
US7741450B2 (en) 2010-06-22
KR20080099314A (ko) 2008-11-12
CA2961031C (en) 2020-02-25
IL193011A (en) 2015-06-30
LT1981909T (lt) 2017-01-10
CY1118709T1 (el) 2017-07-12
PT1981909T (pt) 2017-01-18
JP5210889B2 (ja) 2013-06-12

Similar Documents

Publication Publication Date Title
KR101395515B1 (ko) 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
KR101950306B1 (ko) Ｉｌ-17ａ 및 ｉｌ-17ｆ에 결합하는 항체 분자
CA2537876C (en) Antibodies to m-csf
AU2013355172B2 (en) BCMA antigen binding proteins
US8993731B2 (en) PD-1 antibody
KR101329843B1 (ko) Ｃｄ25에 대한 인간 모노클로날 항체
RU2746926C2 (ru) Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких
CN101861336A (zh) 人gm-csf抗原结合蛋白质
KR20190005873A (ko) 항-pacap 항체 및 그의 용도
CN112823167A (zh) 抗-αvβ8抗体和组合物及其用途
CN106659774A (zh) 用于治疗自身免疫和炎性病症的方法和组合物
KR20180002685A (ko) 항-pacap 항체 및 그의 용도
MXPA05003907A (es) Anticuerpos neutralizantes anti-ifn-gamma humano como inhibidores selectivos de la ruta del ifn-gamma.
SK18122002A3 (sk) Protilátky proti ľudskému MCP-1
EA031524B1 (ru) Антитела, связывающие ил-23
CN103328508A (zh) 针对制癌蛋白m(osm)的抗原结合蛋白
AU2013201228B2 (en) Antigenic gm-csf peptides and antibodies to gm-csf
CN114144435B (zh) 针对人trem-1的抗体及其用途
RU2812478C2 (ru) АНТИ-αvβ8 АНТИТЕЛА И КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
HK40042102A (en) Anti-avb8 antibodies and compositions and uses thereof

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

St.27 status event code: A-5-5-V10-V11-apl-PJ0202

J301 Trial decision

Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20150106

Effective date: 20150715

Free format text: TRIAL NUMBER: 2015105000002; TRIAL DECISION FOR CORRECTION REQUESTED 20150106

Effective date: 20150715

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20150715

Appeal event data comment text: Appeal Kind Category : Correction, Appeal Ground Text : 1395515

Appeal request date: 20150106

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015105000002

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20150930

Republication note text: Request for Public Notice of Correction Statement

Gazette number: 1013955150000

Gazette reference publication date: 20140514

FPAY Annual fee payment

Payment date: 20170425

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180426

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20190424

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20200428

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20210429

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20220427

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250509

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250509

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250509